Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats
- PMID: 17720206
- DOI: 10.1016/j.neuropharm.2007.07.004
Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats
Abstract
Tobacco smoking and obesity are worldwide important health problems with a growing impact in adolescent and young adults. One of the consequences of nicotine withdrawal is an increase in body weight that can act as a risk factor to relapse. Experimental therapies with a cannabinoid receptor antagonist have been recently proposed for both cigarette smoking and complicated overweight. In the present study, we aimed to investigate metabolic and hormonal effects of chronic nicotine treatment (during treatment and in abstinence) in an animal model of adolescence as well as to address the pharmacological effects of the novel selective CB1 cannabinoid receptor antagonist, SR 147778 (Surinabant). Adolescence (postnatal days 37-44) and/or post-adolescence (postnatal days 45-59) administration of Surinabant reduced body weight gain, as well as plasma glucose levels and triglycerides. The drug also reduced insulin and leptin secretion, and increased adiponectin and corticosterone levels. The effects showed sexual dimorphisms and, in general, were more pronounced in females. Chronic exposure to nicotine (0.8 mg/kg), from postnatal days 30-44 did not result in overt effects on food intake or body weight gain. However, it altered certain responses to the administration of Surinabant, both when the two drugs were given simultaneously and when Surinabant was administered during the post-adolescence period, along nicotine withdrawal. The present results indicate that the endogenous cannabinoid system is active as a metabolic modulator during adolescence and that nicotine exposure can induce long-lasting effects on metabolic regulation, altering cannabinoid modulation of energy expenditure and metabolism.
Similar articles
-
Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.Metabolism. 2013 Nov;62(11):1641-50. doi: 10.1016/j.metabol.2013.06.011. Epub 2013 Aug 6. Metabolism. 2013. PMID: 23932644
-
Effects of chronic nicotine on food intake and anxiety-like behaviour in CB(1) knockout mice.Eur Neuropsychopharmacol. 2010 Jun;20(6):369-78. doi: 10.1016/j.euroneuro.2010.02.003. Epub 2010 Feb 26. Eur Neuropsychopharmacol. 2010. PMID: 20189358
-
The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.Neuropharmacology. 2008 Jan;54(1):226-34. doi: 10.1016/j.neuropharm.2007.03.007. Epub 2007 Mar 24. Neuropharmacology. 2008. PMID: 17467748
-
Rimonabant: the first therapeutically relevant cannabinoid antagonist.Life Sci. 2005 Sep 23;77(19):2339-50. doi: 10.1016/j.lfs.2005.04.017. Life Sci. 2005. PMID: 15935395 Review.
-
Genistein--a dietary compound inducing hormonal and metabolic changes.J Steroid Biochem Mol Biol. 2007 Jun-Jul;105(1-5):37-45. doi: 10.1016/j.jsbmb.2007.01.005. Epub 2007 May 17. J Steroid Biochem Mol Biol. 2007. PMID: 17588743 Review.
Cited by
-
Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options.Pharmaceuticals (Basel). 2010 Jan 12;3(1):125-145. doi: 10.3390/ph3010125. Pharmaceuticals (Basel). 2010. PMID: 27713245 Free PMC article. Review.
-
Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats.Psychopharmacology (Berl). 2009 Sep;205(4):655-65. doi: 10.1007/s00213-009-1572-x. Epub 2009 Jun 4. Psychopharmacology (Berl). 2009. PMID: 19495728
-
Activation of the cholinergic antiinflammatory pathway ameliorates obesity-induced inflammation and insulin resistance.Endocrinology. 2011 Mar;152(3):836-46. doi: 10.1210/en.2010-0855. Epub 2011 Jan 14. Endocrinology. 2011. PMID: 21239433 Free PMC article.
-
Adolescence is a period of development characterized by short- and long-term vulnerability to the rewarding effects of nicotine and reduced sensitivity to the anorectic effects of this drug.Behav Brain Res. 2013 Nov 15;257:275-85. doi: 10.1016/j.bbr.2013.10.003. Epub 2013 Oct 10. Behav Brain Res. 2013. PMID: 24120402 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials